8-K: NeuroOne Reports Record $9.1M Revenue, 163% Growth

NeuroOne Medical Technologies Corporation announced preliminary unaudited fiscal year 2025 product revenue of $9.1 million, marking a 163% increase from the prior year, alongside $6.6 million in cash and cash equivalents.

Summary

• Preliminary unaudited total product revenue for the fiscal year ended September 30, 2025, reached approximately $9.1 million.
• This represents a significant 163% increase compared to $3.5 million in total product revenue for fiscal year 2024.
• Cash and cash equivalents were approximately $6.6 million as of September 30, 2025.
• Revenue growth was primarily driven by expanded customer interest and positive outcomes with the OneRF Ablation system for patients suffering from seizures associated with epilepsy.
• Complete financial results for the quarter are expected to be announced in December 2025.
• A virtual investor webinar is scheduled for October 7, 2025, at 8:30 a.m. Eastern Standard Time, to discuss business operations and recent updates.

Sentiment

Score: 8

Explanation: The significant 163% revenue growth and record $9.1 million in product revenue are strong positive indicators. While the results are preliminary and risks are noted, the operational performance appears robust, suggesting positive momentum for the company's core product.

Positives

• Achieved record annual total product revenue of approximately $9.1 million for fiscal year 2025.
• Reported substantial year-over-year revenue growth of 163% compared to $3.5 million in fiscal year 2024.
• Growth was attributed to expanded customer interest and positive outcomes with the OneRF Ablation system.
• Management believes the company is well-positioned to expand the use of its OneRF technology platform.

Negatives

• The financial results are preliminary and unaudited, subject to completion of accounting and interim review procedures, and therefore subject to adjustment.
• No detailed breakdown of expenses, profitability metrics, or net income/loss was provided in this preliminary report.

Risks

• Preliminary financial results are subject to change and may prove to be materially inaccurate upon final review.
• Actual future results may be materially different from expectations due to factors largely outside the company's control.
• Risks related to maintaining compliance with all Nasdaq continued listing requirements.
• Strategic partnerships may not facilitate the commercialization or market acceptance of technology due to supply chain disruptions, labor shortages, or other factors.
• Technology may not perform as expected based on results of pre-clinical and clinical trials.
• Uncertainties associated with the company's capital requirements to achieve business objectives and its ability to raise additional funds.
• Inability to secure or retain coverage or adequate reimbursement for technology.
• Uncertainties inherent in the development process of technology.
• Risks related to changes in regulatory requirements or decisions of regulatory authorities.
• Inaccurate estimation of the size and growth potential of the markets for technology.
• Risks related to clinical trial patient enrollment and the results of clinical trials.
• Inability to protect intellectual property rights.

Future Outlook

NeuroOne expects to announce complete financial results for the quarter in December 2025. Management believes the company is well-positioned to expand the use of its OneRF technology platform, driven by continued customer interest and positive outcomes.

Management Comments

• "Our 2025 revenue growth was driven by expanded customer interest and positive outcomes with the OneRF Ablation system for patients suffering with seizures associated with epilepsy." Dave Rosa, Chief Executive Officer.
• "We believe we are well positioned to expand use of the OneRF technology platform." Dave Rosa, Chief Executive Officer.

Industry Context

NeuroOne operates in the medical technology sector, specifically focusing on neurological disorders such as epilepsy, Parkinson's disease, and chronic pain. The reported revenue growth, driven by the OneRF Ablation system, indicates strong market acceptance and demand for minimally invasive solutions in neurosurgery, aligning with broader trends towards advanced, patient-outcome-focused medical devices.

Stakeholder Impact

• Shareholders: Positive preliminary revenue growth could lead to increased investor confidence and potential share price appreciation. However, the preliminary nature of the results and identified risks warrant caution.
• Customers (Patients/Physicians): Continued positive outcomes and expanded use of the OneRF Ablation system suggest improved surgical care options and outcomes for patients with neurological disorders.
• Employees: Strong revenue growth may indicate business stability and potential for future growth, positively impacting employee morale and job security.

Next Steps

• Host a virtual investor webinar on October 7, 2025, to discuss business operations and recent updates.
• Announce complete financial results for the quarter in December 2025.
• Continue efforts to expand the use of the OneRF technology platform.

Key Dates

Recommendation

While NeuroOne reported impressive preliminary revenue growth of 163% to a record $9.1 million, indicating strong market acceptance for its OneRF Ablation system, these results are unaudited and subject to change. The company also faces several significant risks, including capital requirements, regulatory changes, and the ability to secure adequate reimbursement. Given the strong operational performance but the inherent uncertainties of preliminary data and the outlined risks, a 'hold' recommendation is prudent for investors to await the complete audited financial results and further clarity on risk mitigation strategies.

Keywords

NeuroOne, NMTC, Medical Technologies, Neurological Disorders, Epilepsy, OneRF Ablation, Product Revenue, Financial Results, MedTech, Brain Stimulation, EEG Recording, Ablation Solutions